ETP ALL has been associated with lower frequency of NOTCH1 mutation, lower response to therapy, higher rates of post-induction MRD positivity, and inferior survival compared with non-ETP ALL [89, 98–101]. This evidence concerns the gene NOTCH1 and acute lymphoblastic leukemia.